Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

AIMS/HYPOTHESIS: The aim of the study was to examine the 48 month outcome of treating recent-onset type 1 diabetic patients for 6 days with humanised CD3-antibody, ChAglyCD3. METHODS: Eighty patients, aged 12-39 years, were recruited for a phase 2 multicentre trial and randomised to placebo (n=40) o...

Full description

Bibliographic Details
Main Authors: Keymeulen, B, Walter, M, Mathieu, C, Kaufman, L, Gorus, F, Hilbrands, R, Vandemeulebroucke, E, Van de Velde, U, Crenier, L, De Block, C, Candon, S, Waldmann, H, Ziegler, A, Chatenoud, L, Pipeleers, D
Format: Journal article
Language:English
Published: 2010

Similar Items